Technical Analysis for KIN - Kindred Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 8.41 0.12% 0.01
KIN closed up 0.12 percent on Monday, May 20, 2019, on 38 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical KIN trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Calm After Storm Range Contraction 0.12%
BB Squeeze Ended Range Expansion 0.12%
Below Lower BB Weakness 0.12%
Down 3 Days in a Row Weakness 0.12%
Lower Bollinger Band Touch Weakness 0.12%

Older signals for KIN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Kindred Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for pets. The company is pursuing small molecules and biologics that are in various stages of development for a range of indications in dogs, cats, and horses. Its products include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs and horses; KIND-007, an inhibitor of Bruton's tyrosine kinase; and KIND-006, an agent for gastrointestinal diseases in cats. The company also has a portfolio of other drugs and biologics under development, which comprise anti-IgE antibody for allergic and immune-mediated diseases; canine analog of Enbrel for inflammatory and autoimmune diseases; canine analog of Orencia for immune-mediated diseases; and KIND-504, a cancer vaccine. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Medicine Biotechnology Health Biopharmaceutical Cancer Pain Immunology Immune System Inflammation Osteoarthritis Atopic Dermatitis Gastrointestinal Diseases Immune Mediated Diseases Inflammatory And Autoimmune Diseases Atopy Etanercept Flupirtine Immunoglobulin E
Is KIN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.75
52 Week Low 8.04
Average Volume 205,567
200-Day Moving Average 11.5434
50-Day Moving Average 8.9738
20-Day Moving Average 8.988
10-Day Moving Average 8.912
Average True Range 0.4507
ADX 19.47
+DI 14.9063
-DI 30.8648
Chandelier Exit (Long, 3 ATRs ) 8.3879
Chandelier Exit (Short, 3 ATRs ) 9.4121
Upper Bollinger Band 9.5904
Lower Bollinger Band 8.3856
Percent B (%b) 0.02
BandWidth 13.404539
MACD Line -0.1289
MACD Signal Line -0.0631
MACD Histogram -0.0658
Fundamentals Value
Market Cap 234.1 Million
Num Shares 27.8 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -7.19
Price-to-Sales 0.00
Price-to-Book 2.41
PEG Ratio -0.15
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.03
Resistance 3 (R3) 8.98 8.72 8.92
Resistance 2 (R2) 8.72 8.57 8.75 8.89
Resistance 1 (R1) 8.57 8.47 8.65 8.62 8.85
Pivot Point 8.31 8.31 8.35 8.34 8.31
Support 1 (S1) 8.16 8.16 8.24 8.21 7.97
Support 2 (S2) 7.90 8.06 7.93 7.93
Support 3 (S3) 7.75 7.90 7.90
Support 4 (S4) 7.80